… syndromes, including acute kidney injury, chronic kidney disease, … Adjuvant curative-intent
etoposide and cisplatin are the … Manifestations of kidney disease post allogeneic-SCT include …

… administered in the setting of acute kidney disease or CKD (… with etoposide and bleomycin,
no significant change in kidney … Carmustine is often used in combination with alkyl guanine …

… disease or with cast nephropathy-induced acute kidney injury. … Autologous stem cell
transplantation following high dose … of patients attain dialysis-independence after transplantation.…

… cancer or following hematopoietic stem cell transplantation (… kidney disease or prior episodes
of acute kidney injury (AKI) … High-dose Carboplatin/ Etoposide/Melphalan increases risk …

… using MEDA (methotrexate, etoposide, dexamethasone and … of the standard dose of BEAM
(carmustine 300 mg/m 2 day −… when they had refractory disease to MEDA or relapsed after …

… of chronic kidney disease (CKD) and acute kidney injury can … during carmustine infusion
and can lead to renal hypoperfusion. Nephrotoxicity usually manifests 2–3 weeks after …

… etoposide, ifosfamide, thiotepa ,and carmustine (BCNU) in combination with methotrexate
(MTX) and cytarabine followed by autologous stem cell transplantation … stem cells after the first …

… for autologous HSCT with BEAM conditioning (carmustine 300 mg/m 2 on day 1, etoposide
… administration, often in the context of acute kidney failure. Prevention, early diagnosis, and …

… care, including brief hemodialysis. He received tocilizumab for … an auto-HSCT using
carmustine, etoposide, cytarabine, and … B-cell lymphoma following autologous stem cell transplant …

… early GI and liver complications following autologous (auto-) … chemotherapeutic agents
busulfan, etoposide, melphalan, and … metastatic liver disease and single high dose-carmustine (≥…